xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05968248</url>
    </required_header>
    <id_info>
      <org_study_id>ChinaPLAGH_Xjp</org_study_id>
      <nct_id>NCT05968248</nct_id>
    </id_info>
    <brief_title>Efficacy and Safety of Deep Brain Stimulation in Mesencephalic Locomotor Region（MLR） for Poststroke Hemiplegia</brief_title>
    <official_title>A Randomized Controlled Trial Exploring the Efficacy and Safety of Deep Brain Stimulation in the Treatment of Motor Dysfunction After Stroke#the PASTS-Stroke Study#</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Chinese PLA General Hospital</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Chinese PLA General Hospital</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        Abstract: Background: The leftover movement disorder of stroke patients is one of the main&#xD;
        causes of disability, and there is still no specific solution. Studies have shown that the&#xD;
        improvement of movement disorder symptoms in patients receiving DBS is a potential therapy.&#xD;
        treatment approach. However, at present, there are few large-sample studies in this area at&#xD;
        home and abroad, which cannot well reveal its actual therapeutic effect and safety, and do&#xD;
        not fully understand its potential neural mechanisms, so it is impossible to form a unified&#xD;
        and standardized treatment standard, which limits its wide application in clinical practice.&#xD;
        Objectives: This study aimed to determine the efficacy and safety of hemiplegia recovery&#xD;
        after deep brain electrical stimulation in stroke patients with hemiplegia. Methods/Design:&#xD;
        This was a double-blind randomized cross-over controlled pilot study in which 62 patients&#xD;
        were assigned to receive deep brain stimulation (DBS) and randomized into DBS and control&#xD;
        groups using a randomized controlled study approach, DBS group One month after the operation,&#xD;
        electrical stimulation was started, and the control group was given sham stimulation&#xD;
        treatment. After 3 and 6 months of follow-up, all the machines were turned off. After a&#xD;
        2-week washout period, the control group was turned on, but the DBS group was given sham&#xD;
        stimulation. After the 9th and 12th month of follow-up, all patients were given start-up&#xD;
        treatment, and neuroimaging and various post-stroke motor-related scores were performed for&#xD;
        data collection and analysis. Discussion: The investigators propose a research design and&#xD;
        rationale to explore the effectiveness and safety of DBS in patients with post-stroke&#xD;
        hemiplegia, and provide evidence and reference for DBS in the treatment of post-stroke&#xD;
        dyskinesia. Study limitations are related to the small sample size and short study time&#xD;
        period.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        The incidence of stroke has been more than 20 million stroke patients worldwide, and it has&#xD;
        become the third highest burden disease in the world.The disability rate of stroke is as high&#xD;
        as 60-80%. The movement disorder left by the disease is the main reason for the high burden&#xD;
        of the disease. At present, there is no particularly obvious and effective treatment measure&#xD;
        in clinical practice. If it is not treated in time, it may lead to permanent disability. The&#xD;
        high cost of traditional rehabilitation and the fatigue of rehabilitation training&#xD;
        institutions and family commuting make it difficult for patients to adhere to treatment, and&#xD;
        the treatment effect is poor.Deep Brain Stimulation (DBS) therapy has achieved good&#xD;
        therapeutic effects in many diseases that were considered difficult to treat in the past,&#xD;
        such as Parkinson's, depression and other diseases , so it is applied to In the treatment of&#xD;
        motor function recovery after stroke , many animal experiments and human clinical studies&#xD;
        have confirmed its efficacy .However, the efficacy and safety of DBS in the treatment of&#xD;
        poststroke motor dysfunction have not been verified by clinical randomized controlled trials.&#xD;
  &#xD;
        The invstigators plan to design a multicenter, prospective, randomized, parallel- controlled&#xD;
        equivalent clinical trial, aiming to to explore the efficacy and safety of DBS in the&#xD;
        treatment of motor dysfunction after stroke in the following aspects: (1) improvement rate of&#xD;
        hemiplegia after stroke (2) improvement rate of life quality, mental and cognitive status,&#xD;
        (3)stimulation parameters, (4) adverse effects.&#xD;
  &#xD;
        The main purpose of our design of this study was to provide more clinical evidence for the&#xD;
        use of deep brain stimulation (DBS) in patients with post-stroke motor dysfunction. The&#xD;
        primary objective was to determine the effectiveness and safety of deep brain stimulation&#xD;
        (DBS) for improving motor dysfunction in stroke patients. The secondary purpose is to explore&#xD;
        the mechanism of deep brain stimulation (DBS) in the treatment of neurological function of&#xD;
        post-stroke motor impairment and the improvement of the quality of life and psychosocial&#xD;
        status of patients.&#xD;
  &#xD;
        According to the inclusion and exclusion criteria,the investigators aimed to collect 62&#xD;
        patients who were diagnosed with stroke and left with motor dysfunction. All patients&#xD;
        included in the study will undergo DBS implantation after baseline assessment, and then will&#xD;
        be randomly divided into 2 groups at a ratio of 1:1: DBS treatment group and conventional&#xD;
        rehabilitation group. The DBS electrodes will be implanted into MLR.The other operation&#xD;
        procedures and subsequent follow-up plan are the same. The DBS device will be switched on in&#xD;
        four weeks postoperatively and the optimal stimulation parameters will be used. The&#xD;
        invstigators will record standardized videos and/or complete a series of clinical scales (see&#xD;
        outcome measures) for all patients at baseline, one month postoperatively (after activation&#xD;
        of DBS device), three months postoperatively, six months postoperatively, and one year&#xD;
        postoperatively. Meanwhile, the stimulation parameters and adverse effects will also be&#xD;
        documented.Finally, two professional raters will assess the severity at different timepoints&#xD;
        according to those standardized videos in a blind manner.Intention-to-treatment analysis and&#xD;
        per protocol analysis are both conducted by a professional data analyst.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">September 10, 2023</start_date>
    <completion_date type="Anticipated">November 11, 2027</completion_date>
    <primary_completion_date type="Anticipated">December 12, 2025</primary_completion_date>
    <phase>N/A</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Parallel Assignment</intervention_model>
      <primary_purpose>Treatment</primary_purpose>
      <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Motor function intervention effect: Fugl-Meyer Assessment Scale (FMA)</measure>
      <time_frame>Up to 1 year postoperatively</time_frame>
      <description>Fugl-Meyer Assessment Scale (FMA) was used to measure the motor function of stroke patients. FMA is widely used in clinical motor function assessment and is a quantitative stroke-specific scale used to assess motor function, balance, sensory and joint function in hemiplegic patients. Each of the five domains contains different assessment items, which are scored on a 3-point scale: 0 = unable to perform. 1 = Partially performed, 2 = Fully performed This scale has been found to have good validity and reliability in the stroke population . There are 17 items in total, and the higher the score, the better the motor function. The primary outcome was the change in FMA-UE score at follow-up 4 weeks after the intervention compared with baseline, and the main comparison was between the DBS group and the sham stimulation.</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Overall improvement of clinical symptoms</measure>
      <time_frame>Up to 1 year postoperatively</time_frame>
      <description>The NIHSS score is used to evaluate the degree of neurological deficit in stroke patients. The baseline evaluation can assess the severity of stroke, and the treatment effect can be regularly evaluated after treatment. Scores range from 0 to 42, with higher scores indicating more severe neurological damage. ; Patients with a score of 16 are likely to die; A score of 6 was highly likely to have a good recovery, and for each score increase, the probability of a good prognosis decreased by 17%. The grades are as follows:&#xD;
  0-1: normal or nearly normal;&#xD;
  Score 1-4: minor stroke;&#xD;
  Score 5-15: moderate stroke;&#xD;
  15-20: moderate-to-severe stroke;&#xD;
  Scores 21-42: Severe stroke.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Balance ability</measure>
      <time_frame>Up to 1 year postoperatively</time_frame>
      <description>The balance ability of the participants during the intervention and follow-up period&#xD;
  was assessed by the Biodex Balance System (BBS, USA) [34]. Refined tests of balance ability include: (1) Limit of Stability (LOS): Limit of Stability (LOS) is a sensitive and reliable measure of dynamic balance control, which refers to the movement of the torso in the supporting base in eight different directions. The furthest distance you can go without walking. Quantify the results by calculating the ratio of the straight-line distance from the center of gravity to the target point and the actual path length ; (2) Modified Sensory Integration Balance Clinical Test (m-CTSIB): m-CTSIB is an effective and A clinically meaningful sensory tissue measure , which uses the BBS on participants in four conditions (e.g., eyes open-tight surface, eyes closed-tight surface, eyes open-foam surface, and eyes closed-foam surface).</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Walking function</measure>
      <time_frame>Up to 1 year postoperatively</time_frame>
      <description>Evaluate the space-time parameters such as joint ROM and net muscle moments in the flexion and extension direction of the lower limb joints during self-selected fast walking (such as step length, pace speed, and single support time). Human three-dimensional kinematics and ground reaction forces were acquired by a 10-camera infrared motion capture system (Vicon motion Systems, Oxford, UK) and force platform (Kistler Instruments AG Corp., Switzerland), respectively. A human biomechanical model was established based on Visual 3D (C-Motion, USA), and all gait analysis results were calculated in this software.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Fall risk</measure>
      <time_frame>Up to 1 year postoperatively</time_frame>
      <description>The Tinetti Performance Oriented Mobility Assessment (POMA) will be used to assess fall risk during the intervention and follow-up period. A previous study reported that the POMA is an easy-to-administer task-oriented test with a higher test weight than other tests such as the time-to-go test, standing on one leg test, and functional accessibility test. Reliability, discriminant validity and predictive validity . The possible total score is 28 points, with the lower the total score, the greater the risk of falling.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>ADL executive ability</measure>
      <time_frame>Up to 1 year postoperatively</time_frame>
      <description>Participants' ADL will be assessed by Barthel Index (BI) during the intervention and follow-up period. Previous studies have shown that BI has high internal and internal reliability in the assessment of ADLs in stroke survivors . Business Intelligence consists of 10 items describing different activities; lower scores indicate a higher ADL reliance.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>A 36-item short-form questionnaire (SF-36)</measure>
      <time_frame>Up to 1 year postoperatively</time_frame>
      <description>A 36-item short-form questionnaire (SF-36) will be used to assess participants' quality of life. It is easy to use, accepted by patients, and meets strict reliability and validity criteria. The SF-36 is a self-administered questionnaire containing 36 items that measures health on 8 multi-item dimensions; higher scores indicate better health.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>The incidence of surgical complications and side effects</measure>
      <time_frame>Up to 1 year postoperatively</time_frame>
      <description>Continuously record the subjects' vital signs, physical examination, sleep time and other objective inspection indicators, and compare them before and after the operation; record the improvement of the subjects' subjective symptoms, and compare them before and after the operation.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Hamilton Depression Scale，HAMD</measure>
      <time_frame>Up to 1 year postoperatively</time_frame>
      <description>Hamilton Depression Scale (HAMD), developed by Hamilton in 1960, is the most commonly used scale in clinical assessment of depression. The patients were examined jointly by two trained raters, generally by conversation and observation. After the examination, the two raters scored independently. Scoring reference values: &lt; 7, no depression; 7-17 points, mild depression; 18 to 24 points, moderate depression; &gt; 24, severe depression.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Acceptability of the intervention</measure>
      <time_frame>Up to 1 year postoperatively</time_frame>
      <description>Acceptability of the intervention includes: (1) referral rate - number of referrals by different departments and hospitals divided by all participants (T1); (2) retention rate - participation in completing the study Divide the number of participants (T4) by all participants (T1); (3) dropout rate - the number of dropouts after randomization divided by all participants (T1), interview participants who drop out to determine the reason for their dropout.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Hamilton Anxiety Scale (HAMA)</measure>
      <time_frame>Up to 1 year postoperatively</time_frame>
      <description>The 14-item Hamilton Anxiety Scale (HAMA) was developed by Hamilton in 1959. It is one of the most widely used physician-rated scales in psychiatry. It is mainly used to assess the severity of anxiety symptoms in neurosis and other patients. All items were scored on a 5-point scale from 0 to 4. The criteria for each level were: 0, asymptomatic 1, mild; Score 2, medium; 3 points, heavy; Four points, extremely heavy. The total score ≥29 points, may be severe anxiety; The total score ≥21 points, must have obvious anxiety; Total score ≥14 points, must have anxiety; The total score ≥7 points, may have anxiety; The total score was &lt; 7 and there were no symptoms of anxiety.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>All adverse events</measure>
      <time_frame>Up to 1 year postoperatively</time_frame>
      <description>All adverse events (such as pain and falls) that occurred during the intervention and follow-up will be recorded on the case record form (CRF) through monitoring and self-reporting, and the relevance of the intervention will be assessed. The incidence of adverse events was defined as the number of patients with occurrence divided by all patients (T1).</description>
    </secondary_outcome>
    <number_of_arms>2</number_of_arms>
    <enrollment type="Anticipated">62</enrollment>
    <condition>Stroke Sequelae</condition>
    <arm_group>
      <arm_group_label>MLR-DBS（Deep brain stimulation of the mesencephalic locomotor region）</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>The arm will be switched on one month postoperatively for electrical stimulation therapy, exercise training rehabilitation and EMG-triggered neuromuscular stimulation. Specialist doctors will assess the patient's rehabilitation status through the telerehabilitation system every week, and provide guidance on rehabilitation training and electrical stimulation therapy.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Conventional rehabilitation group</arm_group_label>
      <arm_group_type>Sham Comparator</arm_group_type>
      <description>The arm will l also have DBS surgery and receive the same rehabilitation training under the face-to-face guidance of specialists except for the power-on (sham stimulation, power-on stimulation parameter is 0).</description>
    </arm_group>
    <intervention>
      <intervention_type>Procedure</intervention_type>
      <intervention_name>MLR-DBS</intervention_name>
      <description>An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 1.5mm) will be inserted into theMLR. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously. Device: MLR-DBS devices&#xD;
  (1) DBS electrode: 3387 (Medtronic, Minneapolis, MN, USA) or L302 (PINS Medical, Beijing, China) or 1210(SceneRay, Suzhou, China); (2) Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China); (3) Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China).</description>
      <arm_group_label>MLR-DBS（Deep brain stimulation of the mesencephalic locomotor region）</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Procedure</intervention_type>
      <intervention_name>Conventional rehabilitation group</intervention_name>
      <description>An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 1.5mm) will be inserted into theMLR. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously.The latter will receive the same rehabilitation training under the face-to-face guidance of specialists except for the power-on (sham stimulation, power-on stimulation parameter is 0).</description>
      <arm_group_label>Conventional rehabilitation group</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            1. Meet WHO or international diagnostic criteria for stroke disease;&#xD;
  &#xD;
            2. The first unilateral supratentorial ischemic or hemorrhagic stroke, the condition is&#xD;
               stable after acute treatment of ischemic stroke, the course of disease is 6 months ≤ 1&#xD;
               year, and participate in 2 evaluations (screening and baseline) before enrollment.&#xD;
  &#xD;
            3. Diagnosed by professional physicians combined with brain CT or magnetic resonance&#xD;
               imaging and other imaging techniques;&#xD;
  &#xD;
            4. Between the ages of 18 and 80, male or female&#xD;
  &#xD;
            5. The responsible lesion in the unilateral white matter area indicated by cranial CT or&#xD;
               MRI&#xD;
  &#xD;
            6. Relevant sequelae such as limb dysfunction after stroke, accompanied by unilateral&#xD;
               limb motor dysfunction, proved to be right-handed by standardized examination.&#xD;
  &#xD;
            7. National Institutes of Health Stroke Scale (NIHSS) score from 2 to 20, grades&#xD;
               paralyzed muscle strength, between grades 1 and 4, WISCI II, grade &gt;2 (0-20 items):&#xD;
               Assisted by one or more persons, able to walk at least 10 m, and less responsive to&#xD;
               conventional rehabilitation prior to inclusion.&#xD;
  &#xD;
            8. Perfect clinical data&#xD;
  &#xD;
            9. Stable medical and physical condition with adequate nursing support and appropriate&#xD;
               medical care in the patient's home community.&#xD;
  &#xD;
           10. The patient himself or voluntarily signs the informed consent and is willing to&#xD;
               cooperate with relevant treatment&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            1. Glasgow Coma Scale (GSC) score below 15, Minimum Mental State Examination (MMSE)&#xD;
               assessment for dementia indicated, suffering from mental disturbance and unable to&#xD;
               cooperate with examination or treatment.&#xD;
  &#xD;
            2. Motor and sensory disturbances are not induced by stroke, nor by previous ischemic&#xD;
               stroke, but stroke induced by trauma, brain tumor, etc.&#xD;
  &#xD;
            3. Serious comorbidities, such as malignant tumors, primary heart, liver, kidney or&#xD;
               hematopoietic system diseases.&#xD;
  &#xD;
            4. History of cognitive impairment, mental disorder, drug abuse, drug allergy, and&#xD;
               alcoholism.&#xD;
  &#xD;
            5. Infection or rupture of the skin on the forearm or leg.&#xD;
  &#xD;
            6. Possess a pacemaker, metal stent, plate, or implant susceptible to electrical impulses&#xD;
               in the body (pacemaker or defibrillator, baclofen pump, deep brain stimulator,&#xD;
               Ventricular shunts, shrapnel, etc.).&#xD;
  &#xD;
            7. Pregnant or breast-feeding or have a recent birth plan.&#xD;
  &#xD;
            8. IS CLASSROUS.&#xD;
  &#xD;
            9. Congenital or acquired abnormalities of lower extremities (affecting joints and&#xD;
               bones).&#xD;
  &#xD;
           10. Registration of investigators, their family members, employees, and other dependents.&#xD;
  &#xD;
           11. Severe joint contractures cause loss or limitation of lower limb activities.&#xD;
  &#xD;
           12. Blood system diseases with increased risk of bleeding during surgical intervention.&#xD;
  &#xD;
           13. Participate in another study drug study within 30 days before and during this study.&#xD;
  &#xD;
           14. Unable to complete the basic process, or difficult to maintain compliance and&#xD;
               follow-up.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>80 Years</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Zhiqi Mao, PhD</last_name>
      <role>Principal Investigator</role>
      <affiliation>Chinese PLA General Hospital</affiliation>
    </overall_official>
    <overall_official>
      <last_name>Junpeng Xu, MD</last_name>
      <role>Principal Investigator</role>
      <affiliation>Chinese PLA General Hospital</affiliation>
    </overall_official>
    <overall_official>
      <last_name>Bin Liu, PhD</last_name>
      <role>Study Chair</role>
      <affiliation>Chinese PLA General Hospital</affiliation>
    </overall_official>
    <overall_official>
      <last_name>Di Liu, MD</last_name>
      <role>Study Chair</role>
      <affiliation>Chinese PLA General Hospital</affiliation>
    </overall_official>
    <overall_official>
      <last_name>Haonan Yang, MD</last_name>
      <role>Study Chair</role>
      <affiliation>Chinese PLA General Hospital</affiliation>
    </overall_official>
    <overall_official>
      <last_name>Shufeng Liang, MD</last_name>
      <role>Study Chair</role>
      <affiliation>Chinese PLA General Hospital</affiliation>
    </overall_official>
    <overall_official>
      <last_name>Zhebin Feng, MD</last_name>
      <role>Study Chair</role>
      <affiliation>Chinese PLA General Hospital</affiliation>
    </overall_official>
    <overall_official>
      <last_name>Jun Hong, MD</last_name>
      <role>Study Chair</role>
      <affiliation>Chinese PLA General Hospital</affiliation>
    </overall_official>
    <overall_official>
      <last_name>Rui Hui, MD</last_name>
      <role>Study Chair</role>
      <affiliation>Chinese PLA General Hospital</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Zhiqi Mao, PhD</last_name>
      <phone>8618910155994</phone>
      <email>markmaoqi@126.com</email>
    </overall_contact>
    <overall_contact_backup>
      <last_name>Junpeng Xu, MD</last_name>
      <phone>8613144628367</phone>
      <email>junpengxv@163.com</email>
    </overall_contact_backup>
    <verification_date>July 2023</verification_date>
    <study_first_submitted>July 9, 2023</study_first_submitted>
    <study_first_submitted_qc>July 26, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 1, 2023</study_first_posted>
    <last_update_submitted>July 26, 2023</last_update_submitted>
    <last_update_submitted_qc>July 26, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 1, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Principal Investigator</responsible_party_type>
      <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
      <investigator_full_name>Zhiqi Mao</investigator_full_name>
      <investigator_title>Professor</investigator_title>
    </responsible_party>
    <keyword>Deep brain stimulation;</keyword>
    <keyword>Hemiplegia;</keyword>
    <keyword>Motor recovery;</keyword>
    <keyword>Stroke.</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Stroke</mesh_term>
      <mesh_term>Hemiplegia</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>Yes</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05968248
  org study id: ChinaPLAGH_Xjp
  nct id: NCT05968248
  lead sponsor: 
  has dmc: No
  is fda regulated drug: No
  is fda regulated device: No
  Abstract: Background: The leftover movement disorder of stroke patients is one of the main
        causes of disability, and there is still no specific solution. Studies have shown that the
        improvement of movement disorder symptoms in patients receiving DBS is a potential therapy.
        treatment approach. However, at present, there are few large-sample studies in this area at
        home and abroad, which cannot well reveal its actual therapeutic effect and safety, and do
        not fully understand its potential neural mechanisms, so it is impossible to form a unified
        and standardized treatment standard, which limits its wide application in clinical practice.
        Objectives: This study aimed to determine the efficacy and safety of hemiplegia recovery
        after deep brain electrical stimulation in stroke patients with hemiplegia. Methods/Design:
        This was a double-blind randomized cross-over controlled pilot study in which 62 patients
        were assigned to receive deep brain stimulation (DBS) and randomized into DBS and control
        groups using a randomized controlled study approach, DBS group One month after the operation,
        electrical stimulation was started, and the control group was given sham stimulation
        treatment. After 3 and 6 months of follow-up, all the machines were turned off. After a
        2-week washout period, the control group was turned on, but the DBS group was given sham
        stimulation. After the 9th and 12th month of follow-up, all patients were given start-up
        treatment, and neuroimaging and various post-stroke motor-related scores were performed for
        data collection and analysis. Discussion: The investigators propose a research design and
        rationale to explore the effectiveness and safety of DBS in patients with post-stroke
        hemiplegia, and provide evidence and reference for DBS in the treatment of post-stroke
        dyskinesia. Study limitations are related to the small sample size and short study time
        period.
  The incidence of stroke has been more than 20 million stroke patients worldwide, and it has
        become the third highest burden disease in the world.The disability rate of stroke is as high
        as 60-80%. The movement disorder left by the disease is the main reason for the high burden
        of the disease. At present, there is no particularly obvious and effective treatment measure
        in clinical practice. If it is not treated in time, it may lead to permanent disability. The
        high cost of traditional rehabilitation and the fatigue of rehabilitation training
        institutions and family commuting make it difficult for patients to adhere to treatment, and
        the treatment effect is poor.Deep Brain Stimulation (DBS) therapy has achieved good
        therapeutic effects in many diseases that were considered difficult to treat in the past,
        such as Parkinson's, depression and other diseases , so it is applied to In the treatment of
        motor function recovery after stroke , many animal experiments and human clinical studies
        have confirmed its efficacy .However, the efficacy and safety of DBS in the treatment of
        poststroke motor dysfunction have not been verified by clinical randomized controlled trials.
  
        The invstigators plan to design a multicenter, prospective, randomized, parallel- controlled
        equivalent clinical trial, aiming to to explore the efficacy and safety of DBS in the
        treatment of motor dysfunction after stroke in the following aspects: (1) improvement rate of
        hemiplegia after stroke (2) improvement rate of life quality, mental and cognitive status,
        (3)stimulation parameters, (4) adverse effects.
  
        The main purpose of our design of this study was to provide more clinical evidence for the
        use of deep brain stimulation (DBS) in patients with post-stroke motor dysfunction. The
        primary objective was to determine the effectiveness and safety of deep brain stimulation
        (DBS) for improving motor dysfunction in stroke patients. The secondary purpose is to explore
        the mechanism of deep brain stimulation (DBS) in the treatment of neurological function of
        post-stroke motor impairment and the improvement of the quality of life and psychosocial
        status of patients.
  
        According to the inclusion and exclusion criteria,the investigators aimed to collect 62
        patients who were diagnosed with stroke and left with motor dysfunction. All patients
        included in the study will undergo DBS implantation after baseline assessment, and then will
        be randomly divided into 2 groups at a ratio of 1:1: DBS treatment group and conventional
        rehabilitation group. The DBS electrodes will be implanted into MLR.The other operation
        procedures and subsequent follow-up plan are the same. The DBS device will be switched on in
        four weeks postoperatively and the optimal stimulation parameters will be used. The
        invstigators will record standardized videos and/or complete a series of clinical scales (see
        outcome measures) for all patients at baseline, one month postoperatively (after activation
        of DBS device), three months postoperatively, six months postoperatively, and one year
        postoperatively. Meanwhile, the stimulation parameters and adverse effects will also be
        documented.Finally, two professional raters will assess the severity at different timepoints
        according to those standardized videos in a blind manner.Intention-to-treatment analysis and
        per protocol analysis are both conducted by a professional data analyst.
  allocation: Randomized
  intervention model: Parallel Assignment
  primary purpose: Treatment
  masking: Triple (Participant, Care Provider, Outcomes Assessor)
  measure: Motor function intervention effect: Fugl-Meyer Assessment Scale (FMA)
  time frame: Up to 1 year postoperatively
  description: Fugl-Meyer Assessment Scale (FMA) was used to measure the motor function of stroke patients. FMA is widely used in clinical motor function assessment and is a quantitative stroke-specific scale used to assess motor function, balance, sensory and joint function in hemiplegic patients. Each of the five domains contains different assessment items, which are scored on a 3-point scale: 0 = unable to perform. 1 = Partially performed, 2 = Fully performed This scale has been found to have good validity and reliability in the stroke population . There are 17 items in total, and the higher the score, the better the motor function. The primary outcome was the change in FMA-UE score at follow-up 4 weeks after the intervention compared with baseline, and the main comparison was between the DBS group and the sham stimulation.
  measure: Overall improvement of clinical symptoms
  time frame: Up to 1 year postoperatively
  description: The NIHSS score is used to evaluate the degree of neurological deficit in stroke patients. The baseline evaluation can assess the severity of stroke, and the treatment effect can be regularly evaluated after treatment. Scores range from 0 to 42, with higher scores indicating more severe neurological damage. ; Patients with a score of 16 are likely to die; A score of 6 was highly likely to have a good recovery, and for each score increase, the probability of a good prognosis decreased by 17%. The grades are as follows:
  0-1: normal or nearly normal;
  Score 1-4: minor stroke;
  Score 5-15: moderate stroke;
  15-20: moderate-to-severe stroke;
  Scores 21-42: Severe stroke.
  measure: Balance ability
  time frame: Up to 1 year postoperatively
  description: The balance ability of the participants during the intervention and follow-up period
  was assessed by the Biodex Balance System (BBS, USA) [34]. Refined tests of balance ability include: (1) Limit of Stability (LOS): Limit of Stability (LOS) is a sensitive and reliable measure of dynamic balance control, which refers to the movement of the torso in the supporting base in eight different directions. The furthest distance you can go without walking. Quantify the results by calculating the ratio of the straight-line distance from the center of gravity to the target point and the actual path length ; (2) Modified Sensory Integration Balance Clinical Test (m-CTSIB): m-CTSIB is an effective and A clinically meaningful sensory tissue measure , which uses the BBS on participants in four conditions (e.g., eyes open-tight surface, eyes closed-tight surface, eyes open-foam surface, and eyes closed-foam surface).
  measure: Walking function
  time frame: Up to 1 year postoperatively
  description: Evaluate the space-time parameters such as joint ROM and net muscle moments in the flexion and extension direction of the lower limb joints during self-selected fast walking (such as step length, pace speed, and single support time). Human three-dimensional kinematics and ground reaction forces were acquired by a 10-camera infrared motion capture system (Vicon motion Systems, Oxford, UK) and force platform (Kistler Instruments AG Corp., Switzerland), respectively. A human biomechanical model was established based on Visual 3D (C-Motion, USA), and all gait analysis results were calculated in this software.
  measure: Fall risk
  time frame: Up to 1 year postoperatively
  description: The Tinetti Performance Oriented Mobility Assessment (POMA) will be used to assess fall risk during the intervention and follow-up period. A previous study reported that the POMA is an easy-to-administer task-oriented test with a higher test weight than other tests such as the time-to-go test, standing on one leg test, and functional accessibility test. Reliability, discriminant validity and predictive validity . The possible total score is 28 points, with the lower the total score, the greater the risk of falling.
  measure: ADL executive ability
  time frame: Up to 1 year postoperatively
  description: Participants' ADL will be assessed by Barthel Index (BI) during the intervention and follow-up period. Previous studies have shown that BI has high internal and internal reliability in the assessment of ADLs in stroke survivors . Business Intelligence consists of 10 items describing different activities; lower scores indicate a higher ADL reliance.
  measure: A 36-item short-form questionnaire (SF-36)
  time frame: Up to 1 year postoperatively
  description: A 36-item short-form questionnaire (SF-36) will be used to assess participants' quality of life. It is easy to use, accepted by patients, and meets strict reliability and validity criteria. The SF-36 is a self-administered questionnaire containing 36 items that measures health on 8 multi-item dimensions; higher scores indicate better health.
  measure: The incidence of surgical complications and side effects
  time frame: Up to 1 year postoperatively
  description: Continuously record the subjects' vital signs, physical examination, sleep time and other objective inspection indicators, and compare them before and after the operation; record the improvement of the subjects' subjective symptoms, and compare them before and after the operation.
  measure: Hamilton Depression Scale，HAMD
  time frame: Up to 1 year postoperatively
  description: Hamilton Depression Scale (HAMD), developed by Hamilton in 1960, is the most commonly used scale in clinical assessment of depression. The patients were examined jointly by two trained raters, generally by conversation and observation. After the examination, the two raters scored independently. Scoring reference values: < 7, no depression; 7-17 points, mild depression; 18 to 24 points, moderate depression; > 24, severe depression.
  measure: Acceptability of the intervention
  time frame: Up to 1 year postoperatively
  description: Acceptability of the intervention includes: (1) referral rate - number of referrals by different departments and hospitals divided by all participants (T1); (2) retention rate - participation in completing the study Divide the number of participants (T4) by all participants (T1); (3) dropout rate - the number of dropouts after randomization divided by all participants (T1), interview participants who drop out to determine the reason for their dropout.
  measure: Hamilton Anxiety Scale (HAMA)
  time frame: Up to 1 year postoperatively
  description: The 14-item Hamilton Anxiety Scale (HAMA) was developed by Hamilton in 1959. It is one of the most widely used physician-rated scales in psychiatry. It is mainly used to assess the severity of anxiety symptoms in neurosis and other patients. All items were scored on a 5-point scale from 0 to 4. The criteria for each level were: 0, asymptomatic 1, mild; Score 2, medium; 3 points, heavy; Four points, extremely heavy. The total score ≥29 points, may be severe anxiety; The total score ≥21 points, must have obvious anxiety; Total score ≥14 points, must have anxiety; The total score ≥7 points, may have anxiety; The total score was < 7 and there were no symptoms of anxiety.
  measure: All adverse events
  time frame: Up to 1 year postoperatively
  description: All adverse events (such as pain and falls) that occurred during the intervention and follow-up will be recorded on the case record form (CRF) through monitoring and self-reporting, and the relevance of the intervention will be assessed. The incidence of adverse events was defined as the number of patients with occurrence divided by all patients (T1).
  arm group label: MLR-DBS（Deep brain stimulation of the mesencephalic locomotor region）
  arm group type: Experimental
  description: The arm will be switched on one month postoperatively for electrical stimulation therapy, exercise training rehabilitation and EMG-triggered neuromuscular stimulation. Specialist doctors will assess the patient's rehabilitation status through the telerehabilitation system every week, and provide guidance on rehabilitation training and electrical stimulation therapy.
  arm group label: Conventional rehabilitation group
  arm group type: Sham Comparator
  description: The arm will l also have DBS surgery and receive the same rehabilitation training under the face-to-face guidance of specialists except for the power-on (sham stimulation, power-on stimulation parameter is 0).
  intervention type: Procedure
  intervention name: MLR-DBS
  description: An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 1.5mm) will be inserted into theMLR. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously. Device: MLR-DBS devices
  (1) DBS electrode: 3387 (Medtronic, Minneapolis, MN, USA) or L302 (PINS Medical, Beijing, China) or 1210(SceneRay, Suzhou, China); (2) Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China); (3) Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China).
  arm group label: MLR-DBS（Deep brain stimulation of the mesencephalic locomotor region）
  intervention type: Procedure
  intervention name: Conventional rehabilitation group
  description: An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 1.5mm) will be inserted into theMLR. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously.The latter will receive the same rehabilitation training under the face-to-face guidance of specialists except for the power-on (sham stimulation, power-on stimulation parameter is 0).
  arm group label: Conventional rehabilitation group
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: 80 Years
  healthy volunteers: No
  last name: Zhiqi Mao, PhD
  role: Principal Investigator
  affiliation: Chinese PLA General Hospital
  last name: Junpeng Xu, MD
  role: Principal Investigator
  affiliation: Chinese PLA General Hospital
  last name: Bin Liu, PhD
  role: Study Chair
  affiliation: Chinese PLA General Hospital
  last name: Di Liu, MD
  role: Study Chair
  affiliation: Chinese PLA General Hospital
  last name: Haonan Yang, MD
  role: Study Chair
  affiliation: Chinese PLA General Hospital
  last name: Shufeng Liang, MD
  role: Study Chair
  affiliation: Chinese PLA General Hospital
  last name: Zhebin Feng, MD
  role: Study Chair
  affiliation: Chinese PLA General Hospital
  last name: Jun Hong, MD
  role: Study Chair
  affiliation: Chinese PLA General Hospital
  last name: Rui Hui, MD
  role: Study Chair
  affiliation: Chinese PLA General Hospital
  last name: Zhiqi Mao, PhD
  phone: 8618910155994
  email: markmaoqi@126.com
  last name: Junpeng Xu, MD
  phone: 8613144628367
  email: junpengxv@163.com
  responsible party type: Principal Investigator
  investigator affiliation: Chinese PLA General Hospital
  investigator full name: Zhiqi Mao
  investigator title: Professor
  mesh term: Stroke
  mesh term: Hemiplegia
  sharing ipd: Yes